Semaglutide for postpartum prediabetes

Women who develop diabetes during pregnancy do not simply return to baseline once the baby arrives. Gestational diabetes is one of the strongest known predictors of later type 2 diabetes. A 2020 systematic review in the BMJ put the relative risk at 9.51 compared with women who had normoglycaemic pregnancies^[2]. A new Belgian trial is asking a direct question: if you give these women semaglutide in the window after delivery, can you stop that progression before it starts? The protocol, published in BMJ Open on 23 July 2026, sets out a plan to randomise 252 women across 13 hospitals^[1].

The drug under test is semaglutide, the GLP-1 receptor agonist sold as Ozempic for type 2 diabetes and Wegovy for weight management^[3]. This article covers what the trial is designed to find, why the population is worth a dedicated study, and what the results cannot tell us yet.

What the trial is testing

The study is a double-blind, placebo-controlled randomised trial. It plans to enrol 252 women who have a recent history of gestational diabetes and still have prediabetes after delivery, stratified by body mass index^[1]. Participants are randomised to once-weekly subcutaneous semaglutide 1 mg or matching placebo, and both groups receive a standardised lifestyle intervention. Treatment runs for up to 160 weeks, with follow-up extending to 184 weeks.

The primary outcome is whether a participant develops type 2 diabetes, defined by American Diabetes Association criteria^[1]. Secondary outcomes include the need for diabetes rescue therapy, a return to normal blood glucose, weight loss, insulin sensitivity, beta-cell function, cardiometabolic risk markers, patient-reported outcomes, and cost-effectiveness. The trial is registered as NCT05569772.

Why this population is worth a dedicated trial

Gestational diabetes affects a meaningful share of pregnancies, and the metabolic disturbance it signals often does not resolve after the birth. The BMJ meta-analysis by Vounzoulaki and colleagues pooled studies published through 2019 and found the relative risk of later type 2 diabetes was almost ten times higher in women with prior gestational diabetes (9.51, 95% confidence interval 7.14 to 12.67)^[2]. That risk is concentrated in the years soon after the affected pregnancy, which is exactly the window this trial targets.

Lifestyle change is the standard advice for this group, but it is hard to sustain in the early postpartum months, and lifestyle alone has produced inconsistent results. Semaglutide is a reasonable candidate to test because its effect on weight and glucose is well documented. In the STEP-1 obesity trial, semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks, against 2.4% on placebo^[4]. The prevention trial uses the lower 1 mg dose licensed for type 2 diabetes rather than the higher weight-management dose.

What the results cannot tell us yet

This is a protocol paper, not a results paper. No efficacy or safety findings have been reported^[1]. The trial is still running, and the primary outcome depends on years of follow-up. Until it reports, there is no trial evidence that semaglutide prevents type 2 diabetes in this specific group, only a well-designed plan to look for it.

There are also real constraints on who this would apply to. Semaglutide is a prescription-only medicine, and the postpartum period raises questions the trial has to manage carefully, including breastfeeding and any future pregnancy. This is not a drug to take casually during a phase of life when another pregnancy may be planned. Those are clinical decisions for a prescriber who knows the individual, not something a trial protocol settles on its own.

Where this lands

The trial matters because it moves semaglutide from treating established disease toward preventing it in a group with a clear, measurable risk. If it works, it would give clinicians a concrete option for women who currently get little beyond lifestyle advice. If it does not, that is worth knowing too. For now, the honest summary is that a serious trial is under way and the answer is still years off. For the drug's licensed uses and country-by-country status, see our semaglutide regulation overview.

This article is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any decision about medicines. PeptideMethods.com does not sell, distribute, or facilitate the sale of any medicine or peptide product.